Benzinga

Benzinga Japan

Benzinga

Benzinga Japan

Benzinga

Benzinga Japan
水曜日, 9 02

Gilead Sciences Inc

GILDNASDAQ
Trade with Public
Trade with Public
$149.92
3.582.45%
近くで: Aug 31, 5:00 PM EST
$150.00
3.662.5%
プレマーケット: 5:32 AM EST
配当金: 配当落ち日は13 日後です。
概要ニュース業績予想イベント目標株価財務センチメント株主構成配当比較オプション株式レポート

Gilead Sciences Financials

Gilead Sciences (GILD) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) Est

Gilead Sciences (NASDAQ:GILD) lowers FY2026 GAAP EPS guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) analyst estimate..
Benzinga Newsdesk

PRO
Gilead Sciences Raises FY2026 Adj EPS Guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) Est; Raises FY2026 Sales Guidance from $30.000B-$30.400B to $30.100B-$30.400B vs $30.427B Est

Gilead Sciences (NASDAQ:GILD) raises FY2026 Adj EPS guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) analyst estimate. Raises FY2026 sales outlook from $30.000 billion-$30.400 billion to $30.100
Benzinga Newsdesk

PRO
Gilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate

Gilead Sciences (NASDAQ:GILD) reported quarterly losses of $(6.75) per share which beat the analyst consensus estimate of $(7.24) by 6.64 percent. This is a 435.82 percent decrease over earnings of $2.01 per share from
Benzinga Newsdesk

PRO
Gilead Sciences Raises FY2026 Sales Guidance from $29.600B-$30.000B to $30.000B-$30.400B vs $30.216B Est

Guidance and OutlookFor the full year 2026, Gilead now expects:(in millions, except per share amounts) May 7, 2026 Guidance Comparison to February 10, 2026 Guidance Low EndHigh EndProduct
Benzinga Newsdesk

PRO
Gilead Sciences Lowers FY2026 Adj EPS Guidance from $8.45-$8.85 to $(1.05)-$(0.65) vs $8.66 Est

GILEAD SCIENCES, INC.RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE(1)(unaudited)     (in millions, except percentages and per share amounts) Provided February 10,
Benzinga Newsdesk

PRO
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $6.75-$7.15 to $(3.25)-$(2.85) vs $7.51 Est

GILEAD SCIENCES, INC.RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE(1)(unaudited)     (in millions, except percentages and per share amounts) Provided February 10,
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

Benzinga

Benzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved